Export 22 results:
Author Title Type [ Year
Filters: Author is Mendizabal, Adam [Clear All Filters]
“Randomized Phase III BMT CTN Trial of Calcineurin Inhibitor-Free Chronic Graft-Versus-Host Disease Interventions in Myeloablative Hematopoietic Cell Transplantation for Hematologic Malignancies.”, J Clin Oncol, vol. 40, no. 4, pp. 356-368, 2022.
, “Biologic Assignment Trial of Reduced-Intensity Hematopoietic Cell Transplantation Based on Donor Availability in Patients 50-75 Years of Age With Advanced Myelodysplastic Syndrome.”, J Clin Oncol, vol. 39, no. 30, pp. 3328-3339, 2021.
, “Blood and Marrow Transplant Clinical Trials Network Report on the Development of Novel Endpoints and Selection of Promising Approaches for Graft-versus-Host Disease Prevention Trials.”, Biol Blood Marrow Transplant, vol. 24, no. 6, pp. 1274-1280, 2018.
, “A phase II/III randomized, multicenter trial of prednisone/sirolimus prednisone/ sirolimus/calcineurin inhibitor for the treatment of chronic graft--host disease: BMT CTN 0801.”, Haematologica, vol. 103, no. 11, pp. 1915-1924, 2018.
, “Randomized Comparison of Allogeneic Versus Autologous Mesenchymal Stem Cells for Nonischemic Dilated Cardiomyopathy: POSEIDON-DCM Trial.”, J Am Coll Cardiol, vol. 69, no. 5, pp. 526-537, 2017.
, “Umbilical Cord Blood Transplantation in Children with Acute Leukemia: Impact of Conditioning on Transplantation Outcomes.”, Biol Blood Marrow Transplant, vol. 23, no. 10, pp. 1714-1721, 2017.
, “Autologous hematopoietic cell transplantation for HIV-related lymphoma: results of the BMT CTN 0803/AMC 071 trial.”, Blood, vol. 128, no. 8, pp. 1050-8, 2016.
, “Late Effects after Umbilical Cord Blood Transplantation in Very Young Children after Busulfan-Based, Myeloablative Conditioning.”, Biol Blood Marrow Transplant, vol. 22, no. 9, pp. 1627-1635, 2016.
, “Recommendations for donor human leukocyte antigen assessment and matching for allogeneic stem cell transplantation: consensus opinion of the Blood and Marrow Transplant Clinical Trials Network (BMT CTN).”, Biol Blood Marrow Transplant, vol. 21, no. 1, pp. 4-7, 2015.
, “Autologous mesenchymal stem cells produce concordant improvements in regional function, tissue perfusion, and fibrotic burden when administered to patients undergoing coronary artery bypass grafting: The Prospective Randomized Study of Mesenchymal Stem Ce”, Circ Res, vol. 114, no. 8, pp. 1302-10, 2014.
, “Intracoronary cardiosphere-derived cells after myocardial infarction: evidence of therapeutic regeneration in the final 1-year results of the CADUCEUS trial (CArdiosphere-Derived aUtologous stem CElls to reverse ventricUlar dySfunction).”, J Am Coll Cardiol, vol. 63, no. 2, pp. 110-22, 2014.
, “Mismatched related and unrelated donors for allogeneic hematopoietic cell transplantation for adults with hematologic malignancies.”, Biol Blood Marrow Transplant, vol. 20, no. 10, pp. 1485-92, 2014.
, “Multicenter biologic assignment trial comparing reduced-intensity allogeneic hematopoietic cell transplant to hypomethylating therapy or best supportive care in patients aged 50 to 75 with intermediate-2 and high-risk myelodysplastic syndrome: Blood and M”, Biol Blood Marrow Transplant, vol. 20, no. 10, pp. 1566-72, 2014.
, “A novel reduced-intensity conditioning regimen for unrelated umbilical cord blood transplantation in children with nonmalignant diseases.”, Biol Blood Marrow Transplant, vol. 20, no. 3, pp. 326-36, 2014.
, “Optimizing donor selection for public cord blood banking: influence of maternal, infant, and collection characteristics on cord blood unit quality.”, Transfusion, vol. 54, no. 2, pp. 340-52, 2014.
, “Characteristics of CliniMACS® System CD34-enriched T cell-depleted grafts in a multicenter trial for acute myeloid leukemia-Blood and Marrow Transplant Clinical Trials Network (BMT CTN) protocol 0303.”, Biol Blood Marrow Transplant, vol. 18, no. 5, pp. 690-7, 2012.
, “Comparative outcomes of donor graft CD34+ selection and immune suppressive therapy as graft-versus-host disease prophylaxis for patients with acute myeloid leukemia in complete remission undergoing HLA-matched sibling allogeneic hematopoietic cell transpl”, J Clin Oncol, vol. 30, no. 26, pp. 3194-201, 2012.
, “The Cord Blood Apgar: a novel scoring system to optimize selection of banked cord blood grafts for transplantation (CME).”, Transfusion, vol. 52, no. 2, pp. 272-83, 2012.
, “Intracoronary cardiosphere-derived cells for heart regeneration after myocardial infarction (CADUCEUS): a prospective, randomised phase 1 trial.”, Lancet, vol. 379, no. 9819, pp. 895-904, 2012.
, “Myeloablative transplantation using either cord blood or bone marrow leads to immune recovery, high long-term donor chimerism and excellent survival in chronic granulomatous disease.”, Biol Blood Marrow Transplant, vol. 18, no. 9, pp. 1368-77, 2012.
, “Rationale and design of the Transendocardial Injection of Autologous Human Cells (bone marrow or mesenchymal) in Chronic Ischemic Left Ventricular Dysfunction and Heart Failure Secondary to Myocardial Infarction (TAC-HFT) trial: A randomized, double-blind”, Am Heart J, vol. 161, no. 3, pp. 487-93, 2011.
, “Total colony-forming units are a strong, independent predictor of neutrophil and platelet engraftment after unrelated umbilical cord blood transplantation: a single-center analysis of 435 cord blood transplants.”, Biol Blood Marrow Transplant, vol. 17, no. 9, pp. 1362-74, 2011.
,